Literature DB >> 27113601

Some recent advances in multiple sclerosis.

Claire McCarthy1,2, John Thorpe3,4.   

Abstract

In this article, we review some of the key advances in multiple sclerosis (MS) over the last 3 years. Significant progress has been made in understanding the genetics and pathogenesis of MS. The classification of MS phenotypes has been revised and the landscape of therapeutics is rapidly evolving. We provide a practical summary of the main developments for the practising neurologist.

Entities:  

Keywords:  Classification; Genetics; MRI; Multiple sclerosis; Therapy

Mesh：

Year:  2016        PMID： 27113601     DOI： 10.1007/s00415-016-8124-1

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  44 in total

1.  Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?

Authors:  Bernhard Hemmer
Journal:  Mult Scler       Date:  2015-01-12       Impact factor: 6.312

Review 2.  Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses.

Authors:  Lazaros Belbasis; Vanesa Bellou; Evangelos Evangelou; John P A Ioannidis; Ioanna Tzoulaki
Journal:  Lancet Neurol       Date:  2015-02-04       Impact factor: 44.182

3.  Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Authors:  A J Coles; E Fox; A Vladic; S K Gazda; V Brinar; K W Selmaj; A Skoromets; I Stolyarov; A Bass; H Sullivan; D H Margolin; S L Lake; S Moran; J Palmer; M S Smith; D A S Compston
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

4.  25-Hydroxyvitamin D levels in acute monosymptomatic optic neuritis: relation to clinical severity, paraclinical findings and risk of multiple sclerosis.

Authors:  Gorm Pihl-Jensen; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2015-05-01       Impact factor: 4.849

5.  A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.

Authors:  Paolo Zamboni; Roberto Galeotti; Erica Menegatti; Anna Maria Malagoni; Sergio Gianesini; Ilaria Bartolomei; Francesco Mascoli; Fabrizio Salvi
Journal:  J Vasc Surg       Date:  2009-12       Impact factor: 4.268

6.  Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study.

Authors:  Adipong Brickshawana; Shannon R Hinson; Michael F Romero; Claudia F Lucchinetti; Yong Guo; Mathias Buttmann; Andrew McKeon; Sean J Pittock; Min-Hwang Chang; An-Ping Chen; Thomas J Kryzer; James P Fryer; Sarah M Jenkins; Philippe Cabre; Vanda A Lennon
Journal:  Lancet Neurol       Date:  2014-07-06       Impact factor: 44.182

7.  Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Ludwig Kappos; Heinz Wiendl; Krzysztof Selmaj; Douglas L Arnold; Eva Havrdova; Alexey Boyko; Michael Kaufman; John Rose; Steven Greenberg; Marianne Sweetser; Katherine Riester; Gilmore O'Neill; Jacob Elkins
Journal:  N Engl J Med       Date:  2015-10-08       Impact factor: 91.245

8.  Prospective randomized trial of venous angioplasty in MS (PREMiSe).

Authors:  Adnan H Siddiqui; Robert Zivadinov; Ralph H B Benedict; Yuval Karmon; Jihnhee Yu; Mary L Hartney; Karen L Marr; Vesela Valnarov; Cheryl L Kennedy; Murali Ramanathan; Deepa P Ramasamy; Kresimir Dolic; David W Hojnacki; Ellen Carl; Elad I Levy; L Nelson Hopkins; Bianca Weinstock-Guttman
Journal:  Neurology       Date:  2014-06-27       Impact factor: 9.910

9.  Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial.

Authors:  Linn H Steffensen; Lone Jørgensen; Bjørn Straume; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2011-03-13       Impact factor: 4.849

Review 10.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154
View more
  1 in total

Review 1.  P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes?

Authors:  Aleksandra Szybińska; Wiesława Leśniak
Journal:  Aging Dis       Date:  2017-07-21       Impact factor: 6.745
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.